Massimo Mannelli

List of Publications by Year
in descending order

189 papers	18,954 citations	20759 60 h-index	12910 131 g-index
197 all docs	197 docs citations	197 times ranked	11984 citing authors

#	Article	IF	Citations
1	CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5658-5671.	1.8	1,782
2	Phaeochromocytoma. Lancet, The, 2005, 366, 665-675.	6.3	1,462
3	A Prospective Study of the Prevalence of Primary Aldosteronism in 1,125 Hypertensive Patients. Journal of the American College of Cardiology, 2006, 48, 2293-2300.	1.2	1,236
4	Biochemical Diagnosis of Pheochromocytoma. JAMA - Journal of the American Medical Association, 2002, 287, 1427-34.	3.8	994
5	Adjuvant Mitotane Treatment for Adrenocortical Carcinoma. New England Journal of Medicine, 2007, 356, 2372-2380.	13.9	679
6	Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 92-102.	2.9	581
7	Integrated genomic characterization of adrenocortical carcinoma. Nature Genetics, 2014, 46, 607-612.	9.4	560
8	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell, 2017, 31, 181-193.	7.7	532
9	Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nature Genetics, 2011, 43, 663-667.	9.4	478
10	An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncology, The, 2009, 10, 764-771.	5.1	477
11	Renal Damage in Primary Aldosteronism. Hypertension, 2006, 48, 232-238.	1.3	424
12	Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. European Journal of Cancer, 2012, 48, 1739-1749.	1.3	304
13	Clinically Guided Genetic Screening in a Large Cohort of Italian Patients with Pheochromocytomas and/or Functional or Nonfunctional Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1541-1547.	1.8	284
14	Measurements of Plasma Methoxytyramine, Normetanephrine, and Metanephrine as Discriminators of Different Hereditary Forms of Pheochromocytoma. Clinical Chemistry, 2011, 57, 411-420.	1.5	282
15	MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2012, 18, 2828-2837.	3.2	277
16	Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1999-2008.	1.8	262
17	Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. Nature Reviews Endocrinology, 2017, 13, 233-247.	4.3	198
18	Prognostic factors in stage IIIâ€“IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Annals of Oncology, 2015, 26, 2119-2125.	0.6	196

#	Article	IF	Citations
19	Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. Journal of Hypertension, 2020, 38, 1443-1456.	0.3	190
20	Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippelâ€“Lindau syndrome. Endocrine-Related Cancer, 2004, 11, 897-911.	1.6	184
21	Pheochromocytoma Catecholamine Phenotypes and Prediction of Tumor Size and Location by Use of Plasma Free Metanephrines. Clinical Chemistry, 2005, 51, 735-744.	1.5	177
22	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). Modern Pathology, 2015, 28, 807-821.	2.9	176
23	Spectrum and Prevalence of FP/TMEM127 Gene Mutations in Pheochromocytomas and Paragangliomas. JAMA - Journal of the American Medical Association, 2010, 304, 2611.	3.8	174
24	Body Mass Index Predicts Plasma Aldosterone Concentrations in Overweight-Obese Primary Hypertensive Patients. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2566-2571.	1.8	171
25	Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocrine-Related Cancer, 2010, 18, 97-111.	1.6	169
26	Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term. Hypertension, 2018, 71, 585-591.	1.3	149
27	Comparison of the Captopril and the Saline Infusion Test for Excluding Aldosterone-Producing Adenoma. Hypertension, 2007, 50, 424-431.	1.3	142
28	Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Human Molecular Genetics, 2013, 22, 2169-2176.	1.4	142
29	Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncology, The, 2014, 15, 648-655.	5.1	137
30	Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5Î±-Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 161-171.	1.8	131
31	Angiotensin II Stimulates the Synthesis and Secretion of Vascular Permeability Factor/Vascular Endothelial Growth Factor in Human Mesangial Cells. Journal of the American Society of Nephrology: JASN, 1999, 10, 245-255.	3.0	131
32	Phaeochromocytoma, new genes and screening strategies. Clinical Endocrinology, 2006, 65, 699-705.	1.2	130
33	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes and Endocrinology,the, 2020, 8, 773-781.	5.5	129
34	GermlineNF1Mutational Spectra and Loss-of-Heterozygosity Analyses in Patients with Pheochromocytoma and Neurofibromatosis Type 1. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2784-2792.	1.8	126
35	Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocrine-Related Cancer, 2009, 16, 391-400.	1.6	117
36	Krebs Cycle Metabolite Profiling for Identification and Stratification of Pheochromocytomas/Paragangliomas due to Succinate Dehydrogenase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3903-3911.	1.8	111

#	Article	IF	Citations
37	Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1358-1365.	1.8	108
38	Updated and New Perspectives on Diagnosis, Prognosis, and Therapy of Malignant Pheochromocytoma/Paraganglioma. Journal of Oncology, 2012, 2012, 1-10.	0.6	106
39	Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2367-2374.	1.8	103
40	Analysis of circulating microRNAs in adrenocortical tumors. Laboratory Investigation, 2014, 94, 331-339.	1.7	98
41	CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 312-318.	1.8	96
42	Novel Somatic Mutations in the Catalytic Subunit of the Protein Kinase A as a Cause of Adrenal Cushing's Syndrome: A European Multicentric Study. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2093-E2100.	1.8	92
43	Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. Journal of Hypertension, 2007, 25, 1433-1442.	0.3	90
44	Age at Diagnosis of Pheochromocytoma Differs According to Catecholamine Phenotype and Tumor Location. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 375-384.	1.8	90
45	Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. European Journal of Endocrinology, 2005, 153, 307-315.	1.9	86
46	Genetic screening for pheochromocytoma: should SDHC gene analysis be included?. Journal of Medical Genetics, 2007, 44, 586-587.	1.5	86
47	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nature Reviews Endocrinology, 2021, 17, 435-444.	4.3	80
48	Subclinical phaeochromocytoma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 507-515.	2.2	76
49	The Reticulin Algorithm for Adrenocortical Tumor Diagnosis. American Journal of Surgical Pathology, 2013, 37, 1433-1440.	2.1	75
50	Opposing effects of HIF1Î± and HIF2Î± on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYCâ€associated factor X. International Journal of Cancer, 2014, 135, 2054-2064.	2.3	72
51	Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients. Endocrine-Related Cancer, 2012, 19, 149-155.	1.6	71
52	Within-Patient Reproducibility of the Aldosterone:Renin Ratio in Primary Aldosteronism. Hypertension, 2010, 55, 83-89.	1.3	70
53	Thiazolidinediones Inhibit Growth and Invasiveness of the Human Adrenocortical Cancer Cell Line H295R. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1332-1339.	1.8	68
54	Elevated Serum Interferon-Î³-Inducible Chemokine-10/CXC Chemokine Ligand-10 in Autoimmune Primary Adrenal Insufficiency andin VitroExpression in Human Adrenal Cells Primary Cultures after Stimulation with Proinflammatory Cytokines. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2357-2363.	1.8	66

#	Article	IF	Citations
55	Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma. American Journal of Physiology - Endocrinology and Metabolism, 2008, 295, E1223-E1233.	1.8	66
56	Prognostic factors in ectopic Cushingâ€™s syndrome due to neuroendocrine tumors: a multicenter study. European Journal of Endocrinology, 2017, 176, 453-461.	1.9	66
57	Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3526-3538.	1.8	65
58	Management and Treatment of Pheochromocytomas and Paragangliomas. Annals of the New York Academy of Sciences, 2006, 1073, 405-416.	1.8	64
59	Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells. Endocrine-Related Cancer, 2013, 20, 537-550.	1.6	64
60	Quantitative Value of Aldosteroneâ€Renin Ratio for Detection of Aldosteroneâ€Producing Adenoma: The Aldosteroneâ€Renin Ratio for Primary Aldosteronism (AQUARR) Study. Journal of the American Heart Association, 2017, 6, .	1.6	64
61	PheoSeq. Journal of Molecular Diagnostics, 2017, 19, 575-588.	1.2	63
62	Adrenal masses in neoplastic patients. Surgical Endoscopy and Other Interventional Techniques, 2001, 15, 90-93.	1.3	61
63	Functional study in a yeast model of a novel succinate dehydrogenase subunit B gene germline missense mutation (C191Y) diagnosed in a patient affected by a glomus tumor. Human Molecular Genetics, 2009, 18, 1860-1868.	1.4	60
64	Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma. Genetics in Medicine, 2019, 21, 705-717.	1.1	60
65	Gene Expression Profiling of Benign and Malignant Pheochromocytoma. Annals of the New York Academy of Sciences, 2006, 1073, 541-556.	1.8	59
66	Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma. JAMA Oncology, 2019, 5, 1440.	3.4	57
67	Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma. Theranostics, 2019, 9, 4946-4958.	4.6	54
68	DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers. Clinical Cancer Research, 2015, 21, 3020-3030.	3.2	53
69	Evaluation and diagnostic potential of circulating extracellular vesicle-associated microRNAs in adrenocortical tumors. Scientific Reports, 2017, 7, 5474.	1.6	51
70	Endogenous Dopamine (DA) and DA2 Receptors: A Mechanism Limiting Excessive Sympathetic-Adrenal Discharge in Humans*. Journal of Clinical Endocrinology and Metabolism, 1988, 66, 626-631.	1.8	49
71	Progress in Primary Aldosteronism: Present Challenges and Perspectives. Hormone and Metabolic Research, 2010, 42, 374-381.	0.7	49
72	Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. Endocrine-Related Cancer, 2005, 12, 263-272.	1.6	47

#	Article	IF	Citations
73	Rosiglitazone Inhibits Adrenocortical Cancer Cell Proliferation by Interfering with the IGF-IR Intracellular Signaling. PPAR Research, 2008, 2008, 1-11.	1.1	47
74	Expression of the Novel Adrenocorticotropin-Responsive Gene Selective Alzheimerâ€™s Disease Indicator-1 in the Normal Adrenal Cortex and in Adrenocortical Adenomas and Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1332-1339.	1.8	46
75	Low-Dose C-Type Natriuretic Peptide Does Not Affect Cardiac and Renal Function in Humans. Hypertension, 1998, 31, 802-808.	1.3	45
76	In Vivo Evidence That Endogenous Dopamine Modulates Sympathetic Activity in Man. Hypertension, 1999, 34, 398-402.	1.3	45
77	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. Genetics in Medicine, 2018, 20, 1652-1662.	1.1	45
78	DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. Journal of Clinical Endocrinology and Metabolism, 2016, 102, jc.2016-3205.	1.8	44
79	H-RAS Mutations Are Restricted to Sporadic Pheochromocytomas Lacking Specific Clinical or Pathological Features: Data From a Multi-Institutional Series. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1376-E1380.	1.8	42
80	Epigenetic Mutation of the Succinate Dehydrogenase C Promoter in a Patient With Two Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 359-363.	1.8	42
81	Cushingâ€™s Syndrome in a Patient with Bilateral Macronodular Adrenal Hyperplasia Responding to Cisapride: An in Vivo and in Vitro Study. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4616-4622.	1.8	41
82	Metformin as a new anti-cancer drug in adrenocortical carcinoma. Oncotarget, 2016, 7, 49636-49648.	0.8	37
83	Effects of Different Dopaminergic Antagonists on Bromocriptine-Induced Inhibition of Norepinephrine Release*. Journal of Clinical Endocrinology and Metabolism, 1984, 59, 74-78.	1.8	36
84	Pheochromocytoma in rats with multiple endocrine neoplasia (MENX) shares gene expression patterns with human pheochromocytoma. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18493-18498.	3.3	36
85	Detection of Circulating Tumor Cells in Patients With Adrenocortical Carcinoma: A Monocentric Preliminary Study. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3731-3738.	1.8	36
86	Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney International, 2012, 82, 1215-1222.	2.6	35
87	Human fetal adrenal cells retain ageâ€related stemâ€and endocrineâ€differentiation potential in culture. FASEB Journal, 2019, 33, 2263-2277.	0.2	34
88	Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3491-3498.	1.8	33
89	Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model. Endocrine-Related Cancer, 2010, 17, 169-177.	1.6	32
90	Telomerase Activity Is Significantly Enhanced in Malignant Adrenocortical Tumors in Comparison to Benign Adrenocortical Adenomas. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 468-470.	1.8	31

#	Article	IF	Citations
91	A study on human adrenal secretion. Measurement of epinephrine, norepinephrine, dopamine and Cortisol in peripheral and adrenal venous blood under surgical stress. Journal of Endocrinological Investigation, 1982, 5, 91-95.	1.8	30
92	Perioperative Management of Pheochromocytoma/Paraganglioma: Is There a State of the Art?. Hormone and Metabolic Research, 2012, 44, 373-378.	0.7	28
93	Fascin-1 Is a Novel Prognostic Biomarker Associated With Tumor Invasiveness in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1712-1724.	1.8	28
94	New insights in the clinical and translational relevance of miR483-5p in adrenocortical cancer. Oncotarget, 2017, 8, 65525-65533.	0.8	28
95	2D-DIGE proteomic analysis identifies new potential therapeutic targets for adrenocortical carcinoma. Oncotarget, 2015, 6, 5695-5706.	0.8	28
96	Low Sensitivity of Glucagon Provocative Testing for Diagnosis of Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 238-245.	1.8	27
97	Integrative genetic, epigenetic and pathological analysis of paraganglioma reveals complex dysregulation of NOTCH signaling. Acta Neuropathologica, 2013, 126, 575-594.	3.9	27
98	Impaired cardiovascular autonomic response to passive tilting in cirrhosis with ascites. Hepatology, 1996, 24, 1063-1067.	3.6	27
99	The microenvironment induces collective migration in SDHB-silenced mouse pheochromocytoma spheroids. Endocrine-Related Cancer, 2017, 24, 555-564.	1.6	26
100	Potential Pitfalls of SDH Immunohistochemical Detection in Paragangliomas and Phaeochromocytomas Harbouring Germline SDHx Gene Mutation. Anticancer Research, 2017, 37, 805-812.	0.5	26
101	Klinefelterâ€™s syndrome: a study of its hormonal plasma pattern. Journal of Endocrinological Investigation, 1978, 1, 149-154.	1.8	25
102	Diagnostic problems in pheochromocytoma. Journal of Endocrinological Investigation, 1989, 12, 739-757.	1.8	25
103	Yeast model for evaluating the pathogenic significance of SDHB, SDHC and SDHD mutations in PHEO-PGL syndrome. Human Molecular Genetics, 2013, 22, 804-815.	1.4	25
104	Functional and in silico assessment of MAX variants of unknown significance. Journal of Molecular Medicine, 2015, 93, 1247-1255.	1.7	25
105	A nonsecreting pheochromocytoma presenting as an incidental adrenal mass. Report on a case. Journal of Endocrinological Investigation, 1993, 16, 817-822.	1.8	24
106	Uncommon clinical presentations of pheochromocytoma and paraganglioma in two different patients affected by two distinct novel VHL germline mutations. Clinical Endocrinology, 2008, 68, 762-768.	1.2	24
107	Centrally Mediated Effects of Bromocriptine on Cardiac Sympathovagal Balance. Hypertension, 2001, 38, 123-129.	1.3	23
108	Genetics and Biology of Pheochromocytoma. Experimental and Clinical Endocrinology and Diabetes, 2007, 115, 160-165.	0.6	23

#	Article	IF	Citations
109	Mitochondrial function and content in pheochromocytoma/paraganglioma of succinate dehydrogenase mutation carriers. Endocrine-Related Cancer, 2012, 19, 261-269.	1.6	23
110	Role of microenvironment on neuroblastoma SK-N-AS SDHB-silenced cell metabolism and function. Endocrine-Related Cancer, 2015, 22, 409-417.	1.6	23
111	Primary fibroblast co-culture stimulates growth and metabolism in Sdhb-impaired mouse pheochromocytoma MTT cells. Cell and Tissue Research, 2018, 374, 473-485.	1.5	23
112	Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas. Journal of Pathology, 2020, 251, 378-387.	2.1	23
113	Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. Cancers, 2020, 12, 359.	1.7	23
114	Variable Expression of the Transcription Factors cAMP Response Element-Binding Protein and Inducible cAMP Early Repressor in the Normal Adrenal Cortex and in Adrenocortical Adenomas and Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5443-5449.	1.8	22
115	DIAGNOSIS of ENDOCRINE DISEASE: SDHx mutations: beyond pheochromocytomas and paragangliomas. European Journal of Endocrinology, 2018, 178, R11-R17.	1.9	22
116	Dopamine D2 receptor gene expression and binding sites in adrenal medulla and pheochromocytoma [published erratum appears in J Clin Endocrinol Metab 1994 Oct;79(4):1165]. Journal of Clinical Endocrinology and Metabolism, 1994, 79, 56-61.	1.8	22
117	SPECT semiquantitative analysis of adrenocortical (131)I-6 beta iodomethyl-norcholesterol uptake to discriminate subclinical and preclinical functioning adrenal incidentaloma. Journal of Nuclear Medicine, 2003, 44, 1057-64.	2.8	22
118	Patient affected by neurofibromatosis type 1 and thyroid C-cell hyperplasia harboring pathogenic germ-line mutations in both NF1 and RET genes. Gene, 2014, 536, 332-335.	1.0	21
119	Frequent RET protooncogene mutations in multiple endocrine neoplasia type 2A. Journal of Clinical Endocrinology and Metabolism, 1994, 79, 590-594.	1.8	21
120	Usefulness of basal catecholamine plasma levels and clonidine suppression test in the diagnosis of pheochromocytoma. Journal of Endocrinological Investigation, 1987, 10, 377-382.	1.8	20
121	Bilateral massive adrenal hemorrhage due to sepsis: Report of two cases. Journal of Endocrinological Investigation, 1994, 17, 821-824.	1.8	20
122	Xenograft models for preclinical drug testing: Implications for adrenocortical cancer. Molecular and Cellular Endocrinology, 2012, 351, 71-77.	1.6	20
123	Succinate Dehydrogenase Subunit B Mutations Modify Human Neuroblastoma Cell Metabolism and Proliferation. Hormones and Cancer, 2014, 5, 174-184.	4.9	20
124	Effects of naloxone on catecholamine plasma levels in adult men. A dose-response study. European Journal of Endocrinology, 1984, 106, 357-361.	1.9	19
125	Incidental and Metastatic Adrenal Masses. Seminars in Oncology, 2010, 37, 649-661.	0.8	19
126	Role of the PPAR-Î³ System in Normal and Tumoral Pituitary Corticotropic Cells and Adrenal Cells. Neuroendocrinology, 2010, 92, 23-27.	1.2	19

#	Article	IF	Citations
127	Dissecting the Origin of Inducible Brown Fat in Adult Humans Through a Novel Adipose Stem Cell Model from Adipose Tissue Surrounding Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1903-E1912.	1.8	19
128	Systemic hemodynamics and renal function during brain natriuretic peptide infusion in patients with essential hypertension*. American Journal of Hypertension, 1995, 8, 799-807.	1.0	18
129	Pheochromocytomas and Paragangliomas as Causes of Endocrine Hypertension. Frontiers in Endocrinology, 2019, 10, 333.	1.5	18
130	Does endogenous dopamine modulate human sympathetic activity through DA2 receptors?. European Journal of Clinical Pharmacology, 1985, 29, 159-164.	0.8	17
131	Opioid Modulation of Normal and Pathological Human Chromaffin Tissue*. Journal of Clinical Endocrinology and Metabolism, 1986, 62, 577-582.	1.8	17
132	Presence of dopamine-dependent adenylate cyclase activity in human renal cortex. European Journal of Pharmacology, 1988, 149, 351-356.	1.7	17
133	Effects of clonidine on power spectral analysis of heart rate variability in mild essential hypertension. Journal of the Autonomic Nervous System, 1998, 74, 152-159.	1.9	17
134	Immunohistochemical expression of stem cell markers in pheochromocytomas/paragangliomas is associated with SDHx mutations. European Journal of Endocrinology, 2015, 173, 43-52.	1.9	17
135	The Adipose Stem Cell as a Novel Metabolic Actor in Adrenocortical Carcinoma Progression: Evidence from an In Vitro Tumor Microenvironment Crosstalk Model. Cancers, 2019, 11, 1931.	1.7	17
136	The Y606C RET mutation causes a receptor gain of function. Clinical Endocrinology, 2008, 69, 253-258.	1.2	16
137	Cushingâ€™s syndrome in pregnancy. Gynecological Endocrinology, 2015, 31, 102-104.	0.7	16
138	Effects of acute clonidine administration on power spectral analysis of heart rate variability in healthy humans. Autonomic and Autacoid Pharmacology, 1998, 18, 307-312.	0.7	16
139	Sunitinib in the therapy of malignant paragangliomas: report on the efficacy in a SDHB mutation carrier and review of the literature. Archives of Endocrinology and Metabolism, 2017, 61, 90-97.	0.3	15
140	Adrenocortical carcinoma: current treatment options. Current Opinion in Oncology, 2021, 33, 16-22.	1.1	15
141	Oncogenic features of the bone morphogenic protein 7 (BMP7) in pheochromocytoma. Oncotarget, 2015, 6, 39111-39126.	0.8	15
142	Heat Shock Protein 90 as a Prognostic Marker and Therapeutic Target for Adrenocortical Carcinoma. Frontiers in Endocrinology, 2019, 10, 487.	1.5	14
143	Analysis of Telomere Maintenance Related Genes Reveals NOP10 as a New Metastatic-Risk Marker in Pheochromocytoma/Paraganglioma. Cancers, 2021, 13, 4758.	1.7	14
144	Handgrip-induced airway dilation in asthmatic patients with bronchoconstriction induced by MCh inhalation. Journal of Applied Physiology, 2002, 93, 1723-1730.	1.2	13

#	Article	IF	Citations
145	Seladin-1 expression is regulated by promoter methylation in adrenal cancer. BMC Cancer, 2010, 10, 201.	1.1	12
146	Pheochromocytoma Crisis Caused by Contemporary Ergotamine, Caffeine, and Nimesulide Administration. American Journal of the Medical Sciences, 1997, 314, 396-398.	0.4	12
147	Rare diseases in clinical endocrinology: a taxonomic classification system. Journal of Endocrinological Investigation, 2015, 38, 193-259.	1.8	11
148	Regional Differences of Adenylate Cyclase Stimulation by Calcitonin and Calcitonin Gene-Related Peptide in the Human Kidney*. Journal of Clinical Endocrinology and Metabolism, 1989, 69, 491-495.	1.8	10
149	SDH Mutations in Patients Affected by Paraganglioma Syndromes: A Personal Experience. Annals of the New York Academy of Sciences, 2006, 1073, 183-189.	1.8	10
150	The mTORC1 Complex Is Significantly Overactivated in <i>SDHX</i>-Mutated Paragangliomas. Neuroendocrinology, 2017, 105, 384-393.	1.2	10
151	Prognostic and Monitoring Value of Circulating Tumor Cells in Adrenocortical Carcinoma: A Preliminary Monocentric Study. Cancers, 2020, 12, 3176.	1.7	10
152	The Role of Metabolic Changes in Shaping the Fate of Cancer-Associated Adipose Stem Cells. Frontiers in Cell and Developmental Biology, 2020, 8, 332.	1.8	10
153	A case of hyponatremia caused by central hypocortisolism. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 369-375.	2.9	9
154	15 YEARS OF PARAGANGLIOMA: Metabolism and pheochromocytoma/paraganglioma. Endocrine-Related Cancer, 2015, 22, T83-T90.	1.6	9
155	Effects of thyroid replacement therapy on catecholamine plasma levels. Journal of Endocrinological Investigation, 1983, 6, 307-309.	1.8	8
156	Measurement of catecholamines, met-enkephalin, somatostatin and substance P-like immunoreactivities in 12 human pheochromocytomas. Journal of Endocrinological Investigation, 1988, 11, 133-138.	1.8	8
157	Adrenal Incidentaloma: The Influence of a Decision-Making Algorithm on the Short-Term Outcome of Laparoscopy. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2005, 15, 451-459.	0.5	8
158	Pitfalls in Genetic Analysis of Pheochromocytomas/Paragangliomasâ€"Case Report. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2321-2326.	1.8	8
159	A case of malignant insulinoma responsive to somatostatin analogs treatment. BMC Endocrine Disorders, 2018, 18, 98.	0.9	8
160	A further case of giant intrasellar carotid aneurysm mimicking a pituitary adenoma: The relevance of a multivariate approach in differential diagnosis. Italian Journal of Neurological Sciences, 1994, 15, 369-372.	0.1	7
161	Adrenal medulla secretion in Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism, 1994, 78, 1331-1335.	1.8	7
162	Functional significance of germline EPAS1 variants. Endocrine-Related Cancer, 2021, 28, 97-109.	1.6	6

#	Article	IF	Citations
163	Role for Endogenous Dopamine in Modulating Sympathetic-Adrenal Activity in Humans. Hypertension Research, 1995, 18, S79-S86.	1.5	6
164	Stimulated Expression of CXCL12 in Adrenocortical Carcinoma by the PPARgamma Ligand Rosiglitazone Impairs Cancer Progression. Journal of Personalized Medicine, 2021, 11, 1097.	1.1	6
165	Feasibility and safety of minimalâ€incision thyroidectomy for Graves' disease: A prospective, singleâ€center study. Head and Neck, 2013, 35, 1345-1348.	0.9	5
166	Circulating Fascin 1 as a Promising Prognostic Marker in Adrenocortical Cancer. Frontiers in Endocrinology, 2021, 12, 698862.	1.5	5
167	Urinary Endothelin-1 Excretion Is Enhanced by Low-Dose Infusion of Brain Natriuretic Peptide in Normal Humans. Hypertension, 1997, 29, 70-74.	1.3	5
168	A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy. Cancers, 2021, 13, 5831.	1.7	5
169	SDHB and SDHD silenced pheochromocytoma spheroids respond differently to tumour microenvironment and their aggressiveness is inhibited by impairing stroma metabolism. Molecular and Cellular Endocrinology, 2022, 547, 111594.	1.6	5
170	Klinefelterâ€™s syndrome: effects of short-term testosterone administration on hypothalamic-pituitary axis function. Journal of Endocrinological Investigation, 1978, 1, 239-244.	1.8	4
171	Naloxone administration does not affect gonadotrophin secretion in male patients with isolated hypogonadotrophic hypogonadism. European Journal of Endocrinology, 1985, 109, 153-157.	1.9	4
172	Mapping of Human Autoantibody Epitopes on Aromaticl-Amino Acid Decarboxylase. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1096-1105.	1.8	4
173	Metformin Treatment Induces Different Response in Pheochromocytoma/Paraganglioma Tumour Cells and in Primary Fibroblasts. Cancers, 2022, 14, 3471.	1.7	4
174	Dopamine Modulation of Pathological Human Chromaffin Tissue. American Journal of Hypertension, 1990, 3, 22S-24S.	1.0	3
175	Biochemistry, genetics and therapy of malignant pheochromocytomas. Annales D'Endocrinologie, 2009, 70, 166-167.	0.6	3
176	Genetic-clinical profile of subjects with apparently sporadic extra-adrenal paragangliomas. Frontiers in Endocrinology, 2012, 3, 65.	1.5	3
177	SDHx and Non-Chromaffin Tumors: A Mediastinal Germ Cell Tumor Occurring in a Young Man with Germline SDHB Mutation. Medicina (Lithuania), 2020, 56, 561.	0.8	3
178	Il dosaggio delle metanefrine nella diagnosi del feocromocitoma: vantaggi clinici e problematiche di laboratorio. L Endocrinologo, 2010, 11, 65-74.	0.0	2
179	Germline Mutation in KIF1BÎ² Gene Associated with Loss of Heterozygosity: Usefulness of Next-Generation Sequencing in the Genetic Screening of Patients with Pheochromocytoma. International Journal of Endocrinology, 2020, 2020, 1-8.	0.6	2
180	Vasoactive factors in the mechanism of renal sodium handling in cirrhotics: The effect of acute plasma expansion. Pharmacological Research Communications, 1984, 16, 613-635.	0.2	1

#	Article	IF	Citations
181	Impaired cerebral autoregulation in patients with shy-drager syndrome. International Journal of Angiology, 1993, 2, 12-15.	0.2	1
182	Diagnosis and Clinical Pictures. , 2013, , 35-53.		1
183	Renal effects of atrial natriuretic peptide during dopa-decarboxylase inhibition in patients with essential hypertension. European Journal of Clinical Pharmacology, 1993, 44, 423-427.	0.8	0
184	Sindromi feocromocitoma/paraganglioma familiari. L Endocrinologo, 2009, 10, 26-31.	0.0	0
185	Detection of circulating tumor cells in adrenocortical neoplasms. Pathology, 2014, 46, S13-S14.	0.3	0
186	Commentary. Clinical Chemistry, 2016, 62, 929-929.	1.5	0
187	Malignant Pheochromocytoma. , 2019, , 460-468.		0
188	The Endocrine Regulation of Blood Pressure. Endocrinology, 2016, , 1-15.	0.1	0
189	The Endocrine Regulation of Blood Pressure. Endocrinology, 2018, , 611-625.	0.1	0